Tag: NASDAQ:MESO

September 10, 2019

Mesoblast and Grunenthal Partner on Lower Back Pain Cell Therapy

Under the terms of the agreement, Grunenthal will have exclusive rights to commercialize the treatment in Europe and Latin America.
June 11, 2019

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement

Mesoblast (NASDAQ:MESO, ASX:MSB) has announced it has expanded its partnership with JCR Pharmaceuticals for its use of mesenchymal stem cells...
March 25, 2019

Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa

Mesoblast (NASDAQ:MESO,ASX:MSB) has announced its licensee in Japan, JCR Pharmaceuticals, has filed to extend marketing approval for TEMCELL HS for...
January 14, 2019

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

Mesoblast (ASX:MSB;Nasdaq:MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit...
November 16, 2018

Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights

Mesoblast (ASX:MSB; NASDAQ:MESO) today reported strong financial results and provided operational highlights for the first quarter ended September 30, 2018....